These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24673727

  • 1. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study.
    Corazzelli G, Cuccaro A, Morelli E, Arcamone M, De Chiara A, Paccone A, Petrillo A, Ibello F, Aversa C, Esposito M, Volzone F, Saggese M, Capobianco G, Sarno S, Sirica L, Crisci S, De Filippi R, Pinto A.
    Br J Haematol; 2024 Oct; 205(4):1383-1388. PubMed ID: 39091109
    [Abstract] [Full Text] [Related]

  • 3. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH, Anter AH, Awad IA.
    Hematol Oncol Stem Cell Ther; 2012 Apr; 5(1):36-41. PubMed ID: 22446609
    [Abstract] [Full Text] [Related]

  • 5. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
    N Engl J Med; 2010 Aug 12; 363(7):640-52. PubMed ID: 20818855
    [Abstract] [Full Text] [Related]

  • 6. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.
    Br J Haematol; 2016 Mar 12; 172(6):879-88. PubMed ID: 26763986
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y, Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG).
    Leuk Lymphoma; 2013 Jan 12; 54(1):46-52. PubMed ID: 22712838
    [Abstract] [Full Text] [Related]

  • 8. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S, Corrado C, Pavlovsky MA, Prates MV, Zoppegno L, Giunta M, Cerutti I, Palomino E, Pagani F, Lastiri F, Bar D, Bezares RF, Avila G.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 12; 10(3):181-5. PubMed ID: 20511162
    [Abstract] [Full Text] [Related]

  • 9. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
    Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
    J Clin Oncol; 2009 Nov 10; 27(32):5390-6. PubMed ID: 19738111
    [Abstract] [Full Text] [Related]

  • 12. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.
    Lancet Oncol; 2013 Dec 10; 14(13):1348-56. PubMed ID: 24239220
    [Abstract] [Full Text] [Related]

  • 13. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
    Anselmo AP, Cavalieri E, Osti FM, Cantonetti M, De Sanctis V, Alfo M, Amadori S, Enrici RM.
    Anticancer Res; 2004 Dec 10; 24(6):4045-50. PubMed ID: 15736450
    [Abstract] [Full Text] [Related]

  • 14. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Lancet; 2015 Apr 11; 385(9976):1418-27. PubMed ID: 25539730
    [Abstract] [Full Text] [Related]

  • 15. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M.
    Int J Hematol; 2010 Dec 20; 92(5):713-24. PubMed ID: 21076995
    [Abstract] [Full Text] [Related]

  • 17. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2013 Dec 20; 59(2):59-65. PubMed ID: 23814851
    [Abstract] [Full Text] [Related]

  • 18. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M.
    Clin Lymphoma Myeloma; 2009 Apr 20; 9(2):138-44. PubMed ID: 19406724
    [Abstract] [Full Text] [Related]

  • 19. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
    Ohshima R, Motomura S, Hashimoto C, Miyazaki T, Ito S, Takasaki H, Hyo R, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Tomita N, Fujita H, Fujisawa S, Harano H, Kanamori H, Ishigatsubo Y.
    Rinsho Ketsueki; 2010 Dec 20; 51(12):1756-61. PubMed ID: 21258185
    [Abstract] [Full Text] [Related]

  • 20. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA.
    J Clin Oncol; 2004 Jan 01; 22(1):62-8. PubMed ID: 14657226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.